Results 311 to 320 of about 1,245,695 (368)

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives

American Journal of Hematology, EarlyView.
ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley   +1 more source

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review

American Journal of Hematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem‐cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher‐risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and
Nico Gagelmann, Nicolaus Kröger
wiley   +1 more source

Topics of Interest in Women With Myeloproliferative Neoplasms

American Journal of Hematology, EarlyView.
Women with MPN: life‐cycle phases, specific risks, and influencing factors. ABSTRACT Overview Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants ...
Natasha Szuber, Paola Guglielmelli, Naseema Gangat   +2 more
wiley   +1 more source

A Phase II Trial of Geriatric Assessment‐Guided Selection of Treatment Intensity in Older Adults With AML

American Journal of Hematology, EarlyView.
ABSTRACT How to select the appropriate intensity of chemotherapy in older adults with acute myeloid leukemia (AML) remains an unanswered question. In a phase II trial of older adults ≥ 60 years with AML (n = 73), we used geriatric assessment (measures of comorbidity burden, physical and cognitive function) to determine fitness for intensive ...
Vijaya R. Bhatt, Christopher S. Wichman, Thuy T. Koll, Alfred L. Fisher, Tanya M. Wildes, Michael Haddadin, Ann M. Berger, James O. Armitage, Sarah A. Holstein, Lori J. Maness, Krishna Gundabolu   +10 more
wiley   +1 more source

Proximally biased V(D)J recombination in the clonal evolution of IGH alleles in KMT2A::AFF1 BCP‐ALL of all age classes

HemaSphere
Heiko Müller, Frank Dicker, Constance Bär, Wencke Walter, Stephan Hutter, Niroshan Nadarajah, Manja Meggendorfer, Qingsong Gao, Ilaria Iacobucci, Charles G. Mullighan, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach   +12 more
doaj   +1 more source

Blastic Plasmocytoid Dendritic Cell Neoplasm With Pseudo‐Lymphoid Morphology Mimicking Lymphoid Malignancy

American Journal of Hematology, EarlyView.
Romain Ravel‐Chapuis, Gérard Buchonnet, Catherine Boutet, Francine Garnache Ottou, Anne Roggy, Florian Renosi, Olivier Matray, Victor Bobée   +7 more
wiley   +1 more source

Abnormal DNA Methylation Profile Suggests the Extension of the Clinical Spectrum of the SETD2‐Related Disorders to a Syndromic Multiple Tumor Phenotype

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT SETD2 has an essential role in epigenetic regulation. SETD2 pathogenic variants cause neurodevelopmental disorders (SETD2‐NDDs) that most commonly include various degrees of intellectual disability and behavioral disorders, macrocephaly, brain malformations, and generalized overgrowth.
Marie Lucain, Antonio Vitobello, Bekim Sadikovic, Juliette Albuisson, Léa Gaudillat, Martin Chevarin, Julien Maraval, Christel Thauvin‐Robinet, Jennifer Kerkhof, Christophe Philippe, Sophie Nambot, Laurence Faivre   +11 more
wiley   +1 more source

BCR::ABL1‐Positive Acute Myeloid Leukemia

American Journal of Hematology, EarlyView.
Alban Canali, Jean‐Baptiste Rieu, Leopoldine Lapierre, Barbara J. Bain   +3 more
wiley   +1 more source

Neonatally Lethal Fanconi Anemia due to an Amish Founder FANCE Gene Variant; Evidence for Genotype–Phenotype Correlation

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Prenatal and neonatal presentations of multiple congenital anomalies are difficult to diagnose and are associated with an increased risk of lethality. The differential diagnosis of antenatal presentations of radial ray malformations includes Fanconi anemia (FA), an inherited bone marrow failure disorder associated with congenital anomalies in ...
Ethan M. Scott, Olivia K. Wenger, Matthew Adams, Emma L. Baple, Andew Crosby, Joseph Leslie   +5 more
wiley   +1 more source

Hereditary Multiple Osteochondromas and Acute Lymphoblastic Leukemia: A Possible Role for EXT1 and EXT2 in Hematopoietic Malignancies

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Hereditary multiple osteochondromas (HMO) is an autosomal dominant disorder caused by heterozygous deleterious variants in the EXT1 or EXT2 genes. While the clinical core phenotype is well established and mainly consists of bone deformities, limb length discrepancies, multiple benign bone neoplasms, and increased risk of chondrosarcoma, the ...
Francesco Comisi, Carmela Fusco, Rosamaria Mura, Carla Cerruto, Leonardo D'Agruma, Salvatore Carnazzo, Marco Castori, Salvatore Savasta   +7 more
wiley   +1 more source